Optomed (OPTOMED) Q3 2025 earnings summary

Executive summary

• Achieved 47.0% currency-adjusted revenue growth in Q3 2025, with Devices segment as the main growth driver, especially in the US market.

• Devices segment revenue surged 183.6% in Q3, while Software segment revenue declined 8.0% due to timing and price erosion in non-healthcare consulting.

• Aurora AEYE and strategic collaborations, including a global pharma partnership and China joint venture, progressed as planned.

• EBITDA improved to -€536K from -€814K, reflecting better scale and cost management.

• Cash and cash equivalents at period end were €5.3M, with a strong equity ratio in the mid-70s percentage.

Financial highlights

• Q3 2025 revenue rose to €4.42M, up 42.1% year-over-year; Devices: €2.31M (+183.6%), Software: €2.11M (-8.0%).

• Gross margin improved to 61.8% from 54.4% year-over-year; EBITDA margin improved to -12.1% from -26.2%.

• Net loss for Q3: €-1.53M (vs. €-1.6M Q3 2024); EPS: €-0.08 (vs. €-0.09).

• Cash flow from operating activities improved to -€1.04M from -€1.43M.

• Net debt at period end: €-3.68M (improved from €-8.3M y/y).

Outlook and guidance

• Expects full-year 2025 revenue to grow strongly versus 2024, driven by AI-powered screening adoption, new partnerships, and a robust order book.

• US FDA clearance and new collaborations are key growth drivers; software segment faces a challenging market.

• Cost reduction and streamlining program to be implemented in 2026 to further improve profitability.

• Uncertainties include timing of large deals, geopolitics, forex, and a one-off €1.5M order in Q4 2024.